Bolt Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Bolt Biotherapeutics Inc BOLT.OQ reported a quarterly adjusted loss of $4.46​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-9.20. The mean expectation of five analysts for the quarter was for a loss of $6.45 per share. Wall Street expected results to range from $-7.00 to $-6.00 per share.

• Revenue rose 41.5% to $1.80 million from a year ago; analysts expected $819.75 thousand.

• Bolt Biotherapeutics Inc's reported EPS for the quarter was a loss of $4.46​.

• The company reported a quarterly loss of $8.56 million.

• Bolt Biotherapeutics Inc shares had fallen by 2.6% this quarter and lost 47.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $20.00, about 71.9% above its last closing price of $5.62

This summary was machine generated from LSEG data August 14 at 08:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)